Ty21a

Ty21a

"Vivotif" redirects here. Not to be confused with Vi capsular polysaccharide vaccine. For an overview of vaccines against typhoid fever, see Typhoid vaccine.

Ty21a
Vaccine description
Target disease Typhoid
Type Live bacteria
Clinical data
Trade names Vivotif
Pregnancy
category
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration
Oral
Identifiers
CAS Registry Number  YesY
ATC code J07
 YesY   

Ty21a is a live Vi capsular polysaccharide vaccine).[1]

The vaccine is given by mouth. The vaccine is presented either as enteric coated capsules or a liquid suspension. The vaccine must be stored at 2 to 8 °C, but will retain its potency for 14 days at 25°C.[1]

Contents

  • Efficacy and duration of protection 1
  • Dosing 2
  • Trade names 3
  • References 4

Efficacy and duration of protection

The vaccine offers a statistically significant protection for the first seven years, with between 62% to 77% effectiveness at year seven. [2] The vaccine is most commonly used to protect travelers to endemic countries, but some agencies claim that the vaccine could be used in large scale public prevention programs.[1]

Dosing

The recommended dose varies according to country and preparation.

In the US and Canada, an initial course of 4 doses on alternate days is recommended. Full protection is achieved 7 days after the last dose. In the US, a booster dose is recommended after 5 years. In Canada, a booster dose is recommended after 7 years.

In Australia and Europe, an initial course of 3 doses on alternate days is recommended. Protection is achieved 7 days after the last dose. A booster is recommended every 3 years for people living in endemic areas, but every year for people traveling from non-endemic to endemic areas.[3]

Trade names

  • Vivotif (manufactured by Crucell)

References

  1. ^ a b c
  2. ^
  3. ^